product summary
Loading...
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
other
product name :
20x Tris Buffered Saline with Tween 20
catalog :
BUF028
quantity :
500 ml
price :
293 USD
more info or order :
citations: 1
Reference
Wei Y, Jiang Z, Lu J. USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization. Oncol Lett. 2021;21:394 pubmed publisher
product information
Entity Type :
Accessory Reagent
Entity Category :
Other Reagents
ProductCode :
BUF028
Description :
20x Tris Buffered Saline with Tween 20
Specificity :
TBS/Tween
Format :
20 X Concentrate
Applications :
C,P
ApplicationTypes :
Immunohistology - Frozen,Immunohistology - Paraffin
Quantity :
500 ml
Quantity Value :
500
Quantity Type :
ml
Entity Formats :
20 X Concentrate
UNSPSC :
41116126
Product Form :
Concentrated liquid
PriceGBP :
162
PriceEUR :
291
PriceUSD :
293 USD
PriceCHF :
317
PriceSEK :
3172
PriceNOK :
3188
PriceDKK :
2170
NotForSaleInCountries :
KR
more info or order :
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.